Plus: What to expect at the FDA’s Capricor advisory panel meeting
Mark Lennihan/AP
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
We’ve reached the midpoint of the year and, wow, biotech has gone nuts. The sector’s performance in June was especially bonkers.
